Follow
Nicholas James
Nicholas James
Professor of Prostate and Bladder Cancer Research, Institute of Cancer Research
Verified email at icr.ac.uk - Homepage
Title
Cited by
Cited by
Year
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock, R De Wit, WR Berry, J Horti, A Pluzanska, KN Chi, S Oudard, ...
New England Journal of Medicine 351 (15), 1502-1512, 2004
72652004
Alpha emitter radium-223 and survival in metastatic prostate cancer
C Parker, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, SD Fosså, ...
New England Journal of Medicine 369 (3), 213-223, 2013
37052013
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
20972016
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group
Lancet (London, England) 397 (10285), 1637, 2021
2016*2021
Abiraterone for prostate cancer not previously treated with hormone therapy
ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...
New England Journal of Medicine 377 (4), 338-351, 2017
17642017
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ...
The Lancet 392 (10162), 2353-2366, 2018
11012018
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer
ND James, SA Hussain, E Hall, P Jenkins, J Tremlett, C Rawlings, ...
New England Journal of Medicine 366 (16), 1477-1488, 2012
10112012
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
JCC Hu, RS Coffin, CJ Davis, NJ Graham, N Groves, PJ Guest, ...
Clinical cancer research 12 (22), 6737-6747, 2006
6612006
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind …
O Sartor, R Coleman, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, ...
The Lancet Oncology 15 (7), 738-746, 2014
5602014
Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019)
ND James, MR Spears, NW Clarke, DP Dearnaley, JS De Bono, J Gale, ...
European urology 67 (6), 1028-1038, 2015
5202015
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ...
Medrxiv, 2021.06. 15.21258542, 2021
497*2021
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of …
CL Vale, S Burdett, LHM Rydzewska, L Albiges, NW Clarke, D Fisher, ...
The lancet oncology 17 (2), 243-256, 2016
4832016
Required growth facilitators propel axon regeneration across complete spinal cord injury
MA Anderson, TM O’Shea, JE Burda, Y Ao, SL Barlatey, AM Bernstein, ...
Nature 561 (7723), 396-400, 2018
4532018
Confronting false discoveries in single-cell differential expression
JW Squair, M Gautier, C Kathe, MA Anderson, ND James, TH Hutson, ...
Nature communications 12 (1), 5692, 2021
4272021
Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review
G Ploussard, S Daneshmand, JA Efstathiou, HW Herr, ND James, ...
European urology 66 (1), 120-137, 2014
3872014
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior …
CN Sternberg, DP Petrylak, O Sartor, JA Witjes, T Demkow, JM Ferrero, ...
Journal of clinical oncology 27 (32), 5431, 2009
3862009
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ...
Annals of Oncology 26 (8), 1589-1604, 2015
3792015
Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ...
Annals of Oncology 30 (12), 1992-2003, 2019
3692019
Use of prenatal chromosomal microarray: prospective cohort study and systematic review and meta‐analysis
SC Hillman, DJ McMullan, G Hall, FS Togneri, N James, EJ Maher, ...
Ultrasound in Obstetrics & Gynecology 41 (6), 610-620, 2013
3262013
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
CC Parker, NW Clarke, AD Cook, HG Kynaston, PM Petersen, C Catton, ...
The Lancet 396 (10260), 1413-1421, 2020
2992020
The system can't perform the operation now. Try again later.
Articles 1–20